These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36652278)

  • 1. Time to reinvent the wheel for drug causality diagnostic approaches to severe cutaneous adverse reactions.
    Awad A; Trubiano JA
    Australas J Dermatol; 2023 Feb; 64(1):e79-e81. PubMed ID: 36652278
    [No Abstract]   [Full Text] [Related]  

  • 2. The Combined Utility of Ex Vivo IFN-γ Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions.
    Trubiano JA; Strautins K; Redwood AJ; Pavlos R; Konvinse KC; Aung AK; Slavin MA; Thursky KA; Grayson ML; Phillips EJ
    J Allergy Clin Immunol Pract; 2018; 6(4):1287-1296.e1. PubMed ID: 29100867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous drug reactions in children: an update.
    Heelan K; Shear NH
    Paediatr Drugs; 2013 Dec; 15(6):493-503. PubMed ID: 23842849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition and management of severe cutaneous drug reactions.
    Knowles SR; Shear NH
    Dermatol Clin; 2007 Apr; 25(2):245-53, viii. PubMed ID: 17430761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annular drug eruptions.
    Wu WH; Chu CY
    Clin Dermatol; 2022; 40(5):450-465. PubMed ID: 34979270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse cutaneous drug eruptions: current understanding.
    Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
    Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Getting under the skin of adverse drug reactions.
    Hempel C; Martin C
    Orthopedics; 2012 Oct; 35(10):872-6. PubMed ID: 23027476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods for Identifying Culprit Drugs in Cutaneous Drug Eruptions: A Scoping Review.
    Bose R; Ogbalidet S; Boshra M; Finstad A; Marzario B; Huang C; Fahim S
    J Cutan Med Surg; 2022; 26(2):162-168. PubMed ID: 34798794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous drug eruptions associated with the use of biologies and cutaneous drug eruptions mimicking specific skin diseases.
    Seneschal J; Milpied B; Taieb A
    Chem Immunol Allergy; 2012; 97():203-16. PubMed ID: 22613864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous Adverse Reactions of Anticancer Agents.
    Kaul S; Kaffenberger BH; Choi JN; Kwatra SG
    Dermatol Clin; 2019 Oct; 37(4):555-568. PubMed ID: 31466595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous reactions to anticonvulsant medications.
    Hebert AA; Ralston JP
    J Clin Psychiatry; 2001; 62 Suppl 14():22-6. PubMed ID: 11469671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the understanding of severe cutaneous adverse reactions.
    Adler NR; Aung AK; Ergen EN; Trubiano J; Goh MSY; Phillips EJ
    Br J Dermatol; 2017 Nov; 177(5):1234-1247. PubMed ID: 28256714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse cutaneous reactions to medications.
    Kroshinsky D
    Clin Dermatol; 2020; 38(6):605-606. PubMed ID: 33341194
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous drug reactions.
    Rubianes EI; Martín RF; Picó M; González JR
    Bol Asoc Med P R; 1990 Oct; 82(10):434-42. PubMed ID: 2150483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous drug reactions associated with newer antiretroviral agents.
    Martins CR
    J Drugs Dermatol; 2006; 5(10):976-82. PubMed ID: 17373147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic methods for severe cutaneous adverse drug reactions by inpatient dermatologists.
    Park C; Kaffenberger BH; Trinidad JCL; Korman AM
    Int J Dermatol; 2023 Jun; 62(6):e342-e344. PubMed ID: 35726774
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cutaneous adverse drug reactions: clinical aspects and identification].
    Kardaun SH
    Ned Tijdschr Geneeskd; 2013; 157(11):A5823. PubMed ID: 23484517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating in vivo and ex vivo approaches for culprit drug identification in cutaneous adverse drug reactions from non-beta lactam antibiotics.
    Ratanasutiranont N; Mongkolpathumrat P; Rujirawan P; Rerknimitr P; Klaewsongkram J
    Exp Dermatol; 2024 Apr; 33(4):e15074. PubMed ID: 38651364
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of skin testing in the investigation of cutaneous adverse drug reactions.
    Barbaud A; Reichert-Penetrat S; Tréchot P; Jacquin-Petit MA; Ehlinger A; Noirez V; Faure GC; Schmutz JL; Béné MC
    Br J Dermatol; 1998 Jul; 139(1):49-58. PubMed ID: 9764148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric drug eruptions.
    Nguyen E; Gabel CK; Yu J
    Clin Dermatol; 2020; 38(6):629-640. PubMed ID: 33341197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.